UNIVERSAL IBOGAINE RETAINS SHAYNE NYQUVEST AS CAPITAL MARKETS ADVISOR

Mr. Nyquvest has extensive experience in the financial markets, with over 40 years of involvement in assisting companies with strategic fundraising activities in the mining, cannabis and other emerging industries. He served as a former executive vice president of investment banking firm Mackie Research Capital (where he worked from June 2015 for July 2018) and was a founding member of the Canaccord Genuity Group, where he worked as a senior investment advisor from 1993 to 2013.

Mr. Nyquvest co-founded UI in early 2018 after firsthand seeing the transformational effects and potential of ibogaine and was involved in the early development of UI through mid-2021. His vision has been to see this innovative herbal treatment embraced by the mainstream medical community as a solution to help break the epidemic of opioids and other addictions.

Nick KarosUI’s CEO said, “We are delighted that Shayne has recommitted to our strategic business development goals. He has an extensive network in the investment community and was instrumental in UI’s early fundraising and research activities. Health Canada clinical trial application for the use of ibogaine in opioid use disorder and expects to provide additional updates on this in the near future. »

About Universal Ibogaine Inc.

UI is a life sciences company, whose mission is to demonstrate the safety and efficacy of its ibogaine-based detoxification protocol through a planned Canadian clinical trial (focused on disorders related to use of opioids) and ultimately use this protocol worldwide through planned future licensing. Agreements. UI is simultaneously developing a state-of-the-art holistic addiction treatment protocol at its Kelburn recovery center which, when combined with the planned ibogaine detox protocol, aims to revolutionize the way we treat addiction. addiction and significantly improve the lives of individuals and families affected by addiction. .

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICE PROVIDER (AS ITS TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE RELEVANCE OR ACCURACY OF THIS RELEASE.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

‎This press release may contain forward-looking statements and information. Forward-looking information is often characterized by words such as “plans”, “expects”, “projects”, “intends”, “will”, “believes”, “anticipates”, “estimates”, “expected”, ‎‎ “potential”, or other similar words, or statements that certain events or conditions “may”, “should” or “could” occur. Forward-looking statements and information are based on certain key expectations and assumptions made by UI. Although UI believes that the expectations and assumptions on which forward-looking statements are based are reasonable, undue reliance should not be placed on forward-looking statements, as UI cannot guarantee that they will prove to be accurate.

Because forward-looking statements address future events and conditions, they, by their very nature, involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks, including, but not limited to, the risks that required regulatory approvals may not be obtained. Readers are cautioned that the assumptions used in the preparation of this information, although believed to be reasonable by UI at the time of preparation, may prove to be incorrect and readers are cautioned not to place undue reliance on forward-looking information, which speaks only under the conditions in force on the date hereof. UI undertakes no obligation to publicly release any revisions to the forward-looking information contained herein to reflect events or circumstances that occur after the date hereof or to reflect the occurrence of unforeseen events, except as may be required in under applicable securities laws. . ‎

SOURCE Universal Ibogaine Inc.